Resistance of tumours to taxanes causes chemotherapy failure in numerous patients. Resistance is partly due to the low tumour uptake of taxanes and their rapid metabolism. Structural modifications of taxanes can reduce their P-glycoprotein-related efflux or decrease metabolism and consequently increase taxane efficiency. This study compared cytotoxicity and effects of the cell cycle, transport and metabolism of novel taxanes SB-T-1102, SB-T-1103, SB-T-1214 and SB-T-1216, fluorinated SB-T-12851, SB-T-12852, SB-T-12853, SB-T-12854 and IDN5109 with paclitaxel in paclitaxel-sensitive (MDA-MB-435) and paclitaxel-resistant (NCI/ADR-RES) human cancer cells. We have shown before that NCI/ADR-RES cells were 1,000-fold less sensitive to paclitaxel than MDA-MB-435 cells in correspondence to P-glycoprotein overexpression and up to 20-fold lower uptake of the drug in the resistant cells. The uptake of novel taxanes was 1.2 to 3.8 times lower than that of paclitaxel in the MDA-MB-435 cells, but 1.5 to 6.5 times higher in NCI/ADR-RES cells. NCI/ADR-RES cells were correspondingly only 2- to 6.6-fold less sensitive than the MDA-MB-435 cells to novel taxanes. Both cell lines showed minimal metabolism of the novel taxanes which was therefore not responsible for their different sensitivity, the observed differences in their individual efficiency and higher effects than paclitaxel. All novel taxanes caused G(2)/M block of the cell cycle similar to paclitaxel, but lower at concentrations by order of magnitude. Thus, structural modifications of taxanes resulting in their decreased P-glycoprotein-related transport probably caused their higher efficiency than paclitaxel in multidrug-resistant NCI/ADR-RES tumour cells.

Biostatistics and Informatics Group National Institute of Public Health Prague Czech Republic

Department of Cell and Molecular Biology 3rd Faculty of Medicine Charles University Prague Czech Republic

Institute of Chemical Biology and Drug Discovery State University of New York at Stony Brook Stony Brook NY USA

Laboratory of Analytical Biochemistry Biology Centre Academy of Sciences of the Czech Republic České Budějovice Czech Republic

Toxicogenomics Group National Institute of Public Health Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc13012571

003      

CZ-PrNML

005      

20170515135755.0

007      

ta

008      

130404s2012 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s00210-012-0785-4 $2 doi

035    __

$a (PubMed)22855252

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Ehrlichová, Marie $7 xx0067467 $u Toxicogenomics Group, National Institute of Public Health, Prague, Czech Republic

245    10

$a Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells / $c Marie Ehrlichová, Iwao Ojima, Jin Chen, Radka Václavíková, Vlasta Němcová-Fürstová, Jana Vobořilová, Petr Šimek, Stanislav Horský, Pavel Souček, Jan Kovář, Marek Brabec, Ivan Gut

520    9_

$a Resistance of tumours to taxanes causes chemotherapy failure in numerous patients. Resistance is partly due to the low tumour uptake of taxanes and their rapid metabolism. Structural modifications of taxanes can reduce their P-glycoprotein-related efflux or decrease metabolism and consequently increase taxane efficiency. This study compared cytotoxicity and effects of the cell cycle, transport and metabolism of novel taxanes SB-T-1102, SB-T-1103, SB-T-1214 and SB-T-1216, fluorinated SB-T-12851, SB-T-12852, SB-T-12853, SB-T-12854 and IDN5109 with paclitaxel in paclitaxel-sensitive (MDA-MB-435) and paclitaxel-resistant (NCI/ADR-RES) human cancer cells. We have shown before that NCI/ADR-RES cells were 1,000-fold less sensitive to paclitaxel than MDA-MB-435 cells in correspondence to P-glycoprotein overexpression and up to 20-fold lower uptake of the drug in the resistant cells. The uptake of novel taxanes was 1.2 to 3.8 times lower than that of paclitaxel in the MDA-MB-435 cells, but 1.5 to 6.5 times higher in NCI/ADR-RES cells. NCI/ADR-RES cells were correspondingly only 2- to 6.6-fold less sensitive than the MDA-MB-435 cells to novel taxanes. Both cell lines showed minimal metabolism of the novel taxanes which was therefore not responsible for their different sensitivity, the observed differences in their individual efficiency and higher effects than paclitaxel. All novel taxanes caused G(2)/M block of the cell cycle similar to paclitaxel, but lower at concentrations by order of magnitude. Thus, structural modifications of taxanes resulting in their decreased P-glycoprotein-related transport probably caused their higher efficiency than paclitaxel in multidrug-resistant NCI/ADR-RES tumour cells.

650    12

$a antitumorózní látky $x metabolismus $x farmakokinetika $x farmakologie $7 D000970

650    _2

$a buněčné kultury $7 D018929

650    _2

$a buněčný cyklus $x účinky léků $7 D002453

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a viabilita buněk $x účinky léků $7 D002470

650    _2

$a vysokoúčinná kapalinová chromatografie $7 D002851

650    _2

$a mnohočetná léková rezistence $x účinky léků $7 D018432

650    _2

$a chemorezistence $x účinky léků $7 D019008

650    _2

$a lidé $7 D006801

650    _2

$a molekulární struktura $7 D015394

650    12

$a taxoidy $x metabolismus $x farmakokinetika $x farmakologie $7 D043823

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Ojima, Iwao $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA

700    1_

$a Chen, Jin $u Toxicogenomics Group, National Institute of Public Health, Prague, Czech Republic

700    1_

$a Václavíková, Radka $7 xx0142918 $u Toxicogenomics Group, National Institute of Public Health, Prague, Czech Republic

700    1#

$a Fürstová, Vlasta. $7 _AN058812 $u Department of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Vobořilová, Jana

700    1_

$a Šimek, Petr $u Laboratory of Analytical Biochemistry, Biology Centre, Academy of Sciences of the Czech Republic, České Budějovice, Czech Republic

700    1#

$a Horský, Stanislav. $7 xx0280014 $u Toxicogenomics Group, National Institute of Public Health, Prague, Czech Republic

700    1_

$a Souček, Pavel $u Toxicogenomics Group, National Institute of Public Health, Prague, Czech Republic

700    1_

$a Kovář, Jan, $d 1952- $7 jn20040114001 $u Department of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic

700    1_

$a Brabec, Marek $u Biostatistics and Informatics Group, National Institute of Public Health, Prague, Czech Republic

700    1_

$a Gut, Ivan, $d 1936- $7 xx0060370 $u Toxicogenomics Group, National Institute of Public Health, Prague, Czech Republic

773    0_

$w MED00003462 $t Naunyn-Schmiedeberg's archives of pharmacology $x 1432-1912 $g Roč. 385, č. 10 (2012), s. 1035-1048

856    41

$u https://pubmed.ncbi.nlm.nih.gov/22855252 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20130404 $b ABA008

991    __

$a 20170515140140 $b ABA008

999    __

$a ok $b bmc $g 975769 $s 810852

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2012 $b 385 $c 10 $d 1035-1048 $i 1432-1912 $m Naunyn-Schmiedeberg's archives of pharmacology $n Naunyn Schmiedebergs Arch Pharmacol $x MED00003462

GRA    __

$a NS9803 $p MZ0

GRA    __

$a NT11513 $p MZ0

LZP    __

$a Pubmed-20130404